SERUM TARGETED HILIC-MS METABOLOMICS-BASED ANALYSIS IN INFANTS WITH URETEROPELVIC JUNCTION OBSTRUCTION.

Ureteropelvic junction obstruction (UPJO) constitutes the predominant cause of obstructive nephropathy in both neonates and infants, with fundamental questions regarding its mechanism, assessment and treatment that remain still unanswered. The aim of this study was to elucidate potential differences through serum metabolic profiling of surgical cases of infants with UPJO compared to both non-surgical cases and healthy age matched controls. Early diagnosis of renal dysfunction in this cohort based on highlighted biomarkers was the ultimate goal. Thus, serum samples were collected from 20 patients preoperatively, 19 patients with mild stenosis treated conservatively, and 17 healthy controls. All samples were subjected to targeted metabolomics analysis by Hydrophilic Interaction Liquid Chromatography coupled to mass spectrometry (HILIC LC-MS/MS). Both univariate and multivariate statistical analysis were performed. PCA and OPLS-DA score plots showed that the studied groups differed significantly, with a panel of metabolites, including creatinine, L-tryptophan, choline and L-aspartate, distinguishing patients who required surgery from those followed by systematical monitoring as well as from healthy controls, showing high performance as indicators of UPJO disease. The mass spectrometry data is available at the Center for Computational Mass Spectrometry (ccms) website, where it has been assigned as MassIVE MSV000085063 (ftp://massive.ucsd.edu/MSV000085063/). The data can be accessed directly via it's project doi:10.25345/C5HX3M.

[1]  S. Stabouli,et al.  The role of urinary NGAL and serum cystatin C in assessing the severity of ureteropelvic junction obstruction in infants , 2019, Pediatric Nephrology.

[2]  J. Stanslas,et al.  Blood and urine biomarkers in chronic kidney disease: An update. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[3]  Yan Guo,et al.  Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis , 2019, Experimental & Molecular Medicine.

[4]  Ying-Yong Zhao,et al.  Biomarkers of obstructive nephropathy using a metabolomics approach in rat. , 2018, Chemico-biological interactions.

[5]  C. Ching,et al.  Common clinical markers predict end-stage renal disease in children with obstructive uropathy , 2018, Pediatric Nephrology.

[6]  R. Davies The metabolomic quest for a biomarker in chronic kidney disease , 2018, Clinical kidney journal.

[7]  David S. Wishart,et al.  MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis , 2018, Nucleic Acids Res..

[8]  I. Wilson,et al.  Quality Control and Validation Issues in LC-MS Metabolomics. , 2018, Methods in molecular biology.

[9]  R. Coward,et al.  The molecular biology of pelvi-ureteric junction obstruction , 2017, Pediatric Nephrology.

[10]  M. Weitz,et al.  Primary non-surgical management of unilateral ureteropelvic junction obstruction in children: a systematic review , 2017, Pediatric Nephrology.

[11]  H. Mischak,et al.  Urinary biomarkers for renal tract malformations , 2016, Expert review of proteomics.

[12]  Yongyu Zhang,et al.  Metabolomics study of renal fibrosis and intervention effects of total aglycone extracts of Scutellaria baicalensis in unilateral ureteral obstruction rats. , 2016, Journal of ethnopharmacology.

[13]  J. Schanstra,et al.  A capillary electrophoresis coupled to mass spectrometry pipeline for long term comparable assessment of the urinary metabolome , 2016, Scientific Reports.

[14]  X. Qin,et al.  Kidney Tissue Targeted Metabolic Profiling of Unilateral Ureteral Obstruction Rats by NMR , 2016, Front. Pharmacol..

[15]  Liangcai Zhao,et al.  Identification of key metabolic changes in renal interstitial fibrosis rats using metabonomics and pharmacology , 2016, Scientific Reports.

[16]  Tomoyoshi Soga,et al.  Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling , 2016, Scientific Reports.

[17]  Zheng Xiang,et al.  The study on serum and urine of renal interstitial fibrosis rats induced by unilateral ureteral obstruction based on metabonomics and network analysis methods , 2016, Analytical and Bioanalytical Chemistry.

[18]  Ian D Wilson,et al.  Protocol for quality control in metabolic profiling of biological fluids by U(H)PLC-MS. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  R. Chevalier Prognostic factors and biomarkers of congenital obstructive nephropathy , 2016, Pediatric Nephrology.

[20]  N. Vaziri,et al.  Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis , 2015, Scientific Reports.

[21]  G. Theodoridis,et al.  Development and validation of a HILIC‐MS/MS multitargeted method for metabolomics applications , 2015, Electrophoresis.

[22]  P. Brophy,et al.  Metabolomics in pediatric nephrology: emerging concepts , 2015, Pediatric Nephrology.

[23]  Ian D. Wilson,et al.  Advances in liquid chromatography coupled to mass spectrometry for metabolic phenotyping , 2014 .

[24]  B. Fernández-Fernández,et al.  Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. , 2014, Kidney international.

[25]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[26]  I. Wilson,et al.  A QC approach to the determination of day-to-day reproducibility and robustness of LC-MS methods for global metabolite profiling in metabonomics/metabolomics. , 2012, Bioanalysis.

[27]  H. Mischak,et al.  Urinary proteome analysis at 5-year followup of patients with nonoperated ureteropelvic junction obstruction suggests ongoing kidney remodeling. , 2012, The Journal of urology.

[28]  E. Want,et al.  Liquid chromatography-mass spectrometry based global metabolite profiling: a review. , 2012, Analytica chimica acta.

[29]  Ravi Iyengar,et al.  Systems biology of kidney diseases. , 2012, Kidney international.

[30]  I. Burton,et al.  Alterations in urinary metabolites due to unilateral ureteral obstruction in a rodent model. , 2011, Molecular bioSystems.

[31]  S. Kiley,et al.  Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy , 2010, Pediatric Nephrology.

[32]  M. Kilby,et al.  Antenatal ultrasound to predict postnatal renal function in congenital lower urinary tract obstruction: systematic review of test accuracy , 2009, BJOG : an international journal of obstetrics and gynaecology.

[33]  B. Bright,et al.  Operative versus nonoperative management of ureteropelvic junction obstruction in children. , 2009, Urology.

[34]  I. Wilson,et al.  LC-MS-based methodology for global metabolite profiling in metabonomics/metabolomics , 2008 .

[35]  D. Stablein,et al.  Contributions of the Transplant Registry: The 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) * , 2007, Pediatric transplantation.

[36]  H. Mischak,et al.  Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis , 2006, Nature Medicine.

[37]  Guoyao Wu,et al.  Glutathione metabolism and its implications for health. , 2004, The Journal of nutrition.

[38]  S. Zeisel,et al.  Endogenous formation of dimethylamine. , 1985, The Biochemical journal.